Non-oxime pyrazole based inhibitors of B-Raf kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3488-3492

  Newhouse, Bradley J ^a   Hansen, Joshua D ^a   Grina, Jonas ^a   Welch, Mike ^a   Topalov, George ^a   Littman, Nicole ^a   Callejo, Michele ^a   Martinson, Matthew ^a   Galbraith, Sarah ^a   Laird, Ellen R ^a   Brandhuber, Barbara J ^a   Vigers, Guy ^a   Morales, Tony ^a   Woessner, Rich ^a   Randolph, Nikole ^a   Lyssikatos, Joseph ^b   Olivero, Alan ^b  

^a ARRAY BIOPHARMA INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

B Raf; Oxime; Pyrazole

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; HYDROPHOBICITY; MALE; MOUSE; NONHUMAN;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR STRUCTURE; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES;

EID: 79956134834     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.038     Document Type: Article

References (25)

1. R. Hoshino, Y. Chantani, T. Yamori, T. Tsuruo, H. Oka, O. Yoshida, Y. Shimada, S. Ari-I, H. Wada, J. Fujimoto, and M. Kohno Oncogene 18 1999 813 822
2. N. Li, D. Batt, and M. Warmuth Curr. Opin. Invest. Drugs 8 2007 452 456
3. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzles, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W.C. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, and P.A. Futreal Nature 417 2002 949 954
4. Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W.H. Westra, P.W. Ladenson, and D. Sidransky J. Natl. Cancer Inst. 95 8 2003 625 627
5. X. Xu, R.M. Quiros, P. Gattuso, K.B. Ain, and R.A. Prinz Cancer Res. 63 15 2003 4561 4567
6. K. Kalinsky, and F.G. Haluska Expert Rev. Anticancer Ther. 7 2007 715 724
7. D.S. Dhillon, S. Hagan, O. Rath, and W. Kolch Oncogene 26 2007 3279 3290
8. P.T. Wan, M.J. Garnet, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, and R. Marais Cell 116 2004 855 867
9. J.A. McCubrey, M. Milella, A. Tafuri, A.M. Martelli, P. Lunghi, A. Bonai, M. Cervello, J.T. Lee, and L.S. Steelman Curr. Opin. Invest. Drugs 9 2008 614 630
10. J.D. Hansen, J. Grina, B. Newhouse, M. Welch, G. Topalov, N. Littman, M. Callejo, S. Gloor, M. Martinson, E. Laird, B.J. Brandhuber, G. Vigers, T. Morales, R. Woessner, N. Randolph, J. Lyssikatos, and A. Olivero Bioorg. Med. Chem. Lett. 18 2008 4692 4695
11. E.F. Choo, J.P. Driscoll, J. Feng, B. Liederer, E. Plise, N. Randolph, Y. Shin, S. Wong, and Y. Ran Xenobiotica 39 09 2009 700 709
12. R.T. Coutts, R. Dawe, G.W. Dawson, and S.H. Kovach Drug Metab. Disp. 4 1976 35 39
13. S. Heberling, U. Girreser, S. Wolf, and B. Clement Biochem. Pharmacol. 71 2006 354 365
14. PDB accession code 3D4Q.
15. Tautomer preferences were computed using the 6-31G(d) basis set. Frisch, M. J. et al. gaussian98, Revision A.11, Gaussian: Pittsburgh, PA.
16. Free energies of solvation were calculated using SM2.1 Amsol 5.0: Cramer, C. J.; Hawkins, G. D.; Lynch, G. C.; Giesen, D. J.; Rossi, I; Storer, J. W.; Truhlar, D. G.; Liotard, D. A. In AMSOL-version 5.0, Quantum Chemistry Program Exchange Program 606, based in part on AMPAC-version 2.1, Liotard, D. A.; Healy, E. F.; Ruiz, J. M.; Dewar, M. J. S.
17. For assay description see: Laird, E.; Lyssikatos, J.; Welch, M.; Grina, J.; Hansen, J.; Newhouse, B.; Olivero, A.; Topolav, G. WO 2006/084015 A2, 2006.
18. Computed relative energies for the two pyrazole tautomers indicates a significant population of the undesired tautomer also exists (data not shown).
19. L. Ren, S. Wenglowsky, G. Miknis, B. Rast, A.J. Buckmelter, R.J. Ely, S. Schlachter, E.R. Laird, N. Randolph, M. Callejo, M. Martinson, S. Galbraith, B.J. Brandhuber, G. Vigers, T. Morales, W. Voegtli, and J. Lyssikatos Bioorg Med. Chem. Lett. 21 2011 1243 1247
20. Z.-F. Tao, T. Sowin, and N.-H. Lin Tetrahedron Lett. 46 2005 7615 7618
21. W. Hagmann J. Med. Chem. 51 2008 4359 4369
22. H.-J. Bohm, D. Banner, S. Bendels, M. Kansay, B. Kuhn, K. Muller, U. Obst-Sander, and M. Stahl ChemBioChem 5 2004 637 643
23. M.B. van Niel, I. Collins, M.S. Beer, H.B. Broughton, S.K.F. Cheng, S.C. Goodacre, A. Heald, K.L. Locker, A.M. MacLeod, D. Morrison, C.R. Moyes, D. O'Connor, A. Pike, M. Rowley, M.G.N. Russell, B. Sohal, J.A. Stanton, S. Thomas, H. Verrier, A.P. Watt, and J. Castro J. Med. Chem. 42 1999 2087 2104
24. 1H NMR.
25. D.F. Shellhamer, A.A. Briggs, B.M. Miller, J.M. Prince, D.H. Scott, and V.L. Heasley J. Chem. Soc., Perkin Trans. 2 1996 973 977